Biotech M&A – 2021 Deals

Biotech M&A – 2021 Deals

Biotech M&A With a Slow Start in 2020: More Deals to Follow?

DateAcquirer Co.Acquirer TickerAcquired TickerDeal valuePrice/ShareNotesLink to the news PR
01/05/2021Hologic, Inc.HOLXPrivate-German co.$64M-leader in biopsy site markershttps://bwnews.pr/2L3d7lF
01/07/2021 PerkinElmerPKI OXFD $591M $22 infectious disease testing https://bwnews.pr/3ovVucz
01/08/2021ChimerixCMRXPrivate co.$78M-Recurrent H3 K27M-mutant Gliomahttps://bit.ly/39f02O9
02/01/2021Horizon TherapeuticsHZNPVIE$3.05B$53commercial rare disease medicine portfolio with UPLIZNAhttps://bwnews.pr/36vLEQS
02/03/2021Jazz Pharmaceuticals JAZZGWPH$7.2B$$220Cannabidiol - Epidiolex
$200 in cash & $20 in Jazz shares
https://prn.to/3cHtijN
02/23/2021Beam TherapeuticsBEAMPrivate co.$120M in BEAM stockslipid nanoparticle (LNP)https://bit.ly/3urizAI
02/25/2021MerckMRKPAND$1.85B$60IL-2 & Autoimmunehttps://bwnews.pr/3bDZJO7
03/03/2021AmgenAMGNFPRX$1.9B$38Bemarituzumab, Ph3 for Gastric Cancerhttps://prn.to/3qpRPNF
05/05/2021Amryt PharmaAMYTCHMA$296M$5.1280.396 AMYT share x($12.95)https://bit.ly/2PRwTD9
05/10/2021AbbVieABBVSOLY$550M$22.60Rapid Acoustic Pulse device for cellulitehttps://prn.to/3o4kyrL
05/24/2021Xeris PharmaceuticalsXRESSBBPStock & CVR $1/Share in CVRs
NDA for RECORLEV
https://bwnews.pr/3yyoPbH
06/02/2021MorphoSys MORCNST$1.7B$34Hematology-Oncology & Expands into Solid Tumorshttps://bwnews.pr/2STkaRe
07/14/2021Eli LillyLLYPrivate co.>$1Bpeptide- and protein-engineering platformhttps://prn.to/3rkUn1w
07/27/2021AmgenAMGNPrivate co.$900 & CVRAntibodieshttps://bit.ly/3ynYSuX
08/03/2021SanofiSNYTBIO$3.2BmRNA technologyhttps://bit.ly/2VpPXuv
08/23/2021PfizerPFETRIL$2.26B$18.50Immunotherapy CD47https://bit.ly/3zcTQSu
09/08/2021SanofiSNYKDMN$1.9B$9.5Rezurock for cGVHD) https://bit.ly/3ndcdUr
09/30/2021MerckMRKXLRN$11.5B$180Ph-3 Development for the Treatment of PAHhttps://bwnews.pr/3olD15f
10/11/2021Supernus PharmaceuticalsSUPNADMS$400M$8.10$1.00 CVR based on net sales of GOCOVRIhttps://bit.ly/3iLv1af
10/11/2021Pacira BioSciencesPCRXFLXN$630M$8.50CVR up to $8.00 per share in cashhttps://bit.ly/3auQv6J
11/18/2021Novo NordiskNVODRNA$3.3B$38.25ribonucleic acid interference (RNAi) therapeuticshttps://bwnews.pr/3Cr5bPB
12/13/2021PfizerPFEARNA$6.7B$100 immuno-inflammatory diseaseshttps://bwnews.pr/3p2N4w0
12/20/2021SanofiSNYPrivate Co.$1B + $250M milestone-T-cell engagers and cytokine therapieshttps://bit.ly/3sqdCtg
12/22/2021NovartisNVSPrivate Co.$800M + $700M milestone-Gene-Therapy for geographic atrophyhttps://bit.ly/3Fmtwsm

For M&A 2020 full table click here https://www.chimeraresearchgroup.com/biotech-ma-2020-deals/

Recent Press

Slider

Log In

JoinLost Password?